Founded in 2001, Cell>Point is a privately held biopharmaceutical company that is developing and commercializing intra-nuclear molecular imaging and therapeutic compounds for imaging cancer, diabetes, and cardiovascular disease, and the treatment of solid tumor and certain blood borne cancers using platform technologies licensed from The University of Texas M.D. Anderson Cancer Center (“M.D. Anderson”), Houston, Texas.
- Cell>Point enters into license agreement with Vyripharm Biopharmaceuticals for the use of Cell>Point’s In-Situ Hydrogel, N4 Technology and Oligosaccharide (Dual Agent) Technology
- Cell>Point Executes China License with United Eastern Pharmaceutical for Oncardia for Cancer and Heart Disease Diagnostic Imaging
7120 E. Orchard Rd., Suite 350
Centennial, Colorado 80111